Contribution of Circulating Tumour Cells in Drug Development

Jul 19, 2016

Circulating tumour cells (CTCs) are becoming very welcome in the field of oncology, and they are also promising in the clinical field, in the area of drug development. Proof of concept that CTCs may correlate with the prognosis of cancer has been completed for many types already. Also, the CTCs may carry information that is relevant to the disease progression and behaviour and this data cannot be obtained from the primary tumour. Hence they are becoming extremely valuable in the field of drug development and evaluation of candidate medications in pharmaceutical research and industry. Dr Ioannis Papasotiriou, MD at RGCC, ...

Read More

Applications of CRISPR

Jul 19, 2016

Scientific interest in Clustered Regularly Interspaced Palindromic Repeats (CRISPR) systems exploded in 2012/2013 when focus shifted from their natural function as a component of adaptive bacterial immunity to their use as a toolkit to find, cut and replace DNA at a specific location in eukaryotes. Widely considered to be a breakthrough technology, the speed of adoption of this technology has been phenomenal. Catherine Coombes, Senior Patent Attorney at HGF Limited concentrates on applications of CRISPR. ...

Read More

How to Protect Your IP Rights Abroad

Jul 19, 2016

Many life sciences companies which protect their inventions, brands or product designs through patents, trademarks or registered designs in their home country, do not realise that this does not give them automatic protection in other countries. Intellectual property rights are territorial rights, meaning that the protection afforded by a granted patent or a registered trade mark is geographically limited. Jim Robertson at Wynne-Jones IP submits his white paper on IP rights abroad. ...

Read More

Why Agility Holds the Key to Transformation in Life Sciences

Jul 19, 2016

The priority that will unite all life sciences companies in 2016 is the pursuit of greater agility. As long as organisations keep taking a short-term view, investing in standalone information management systems for each new business requirement, the only thing they’ll successfully grow is cost, warns Mark Evenepoel, Group CEO at Amplexor Life Sciences. The real focus should be flexibility and responsiveness to whatever the market demands next. ...

Read More

The Total IDMP Effort – an insight into the data volume of an ISO IDMP submission

Jul 19, 2016

It has, since 2012, been a well-established fact that pharmaceutical companies which have medicinal products or are conducting clinical trials in the European Union (EU) will have to adhere to the ISO standards mandated in EU Regulation 520/2012. With the aim of improving overall pharmacovigilance signal detection and oversight, the European Medicines Agency (EMA) will rely on these standards (11615, 11616, 11238, 11239 & 11240) to achieve this goal. Niels Grønning and Rune Ringsholm Bergendorff at NNIT give us an insight into the data volume of an ISO IDMP submission. ...

Read More